Learn more about Peter Attia’s digital program
#260 ‒ Men’s Sexual Health: why it matters, what can go wrong, and how to fix it | Mohit Khera, M.D., M.B.A., M.P.H.
“Clinicians don’t ask about it. Patients are embarrassed to ask about it. And that’s the suffering in silence.” —Mohit Khera
#258 – AMA #48: Blood pressure—how to measure, manage, and treat high blood pressure
“If you care about your brain, if you care about your heart and if you care about your kidneys, you need low blood pressure. I think we can say that as confidently as we can say almost anything in medicine.” —Peter Attia
#257 ‒ Cognitive decline, neurodegeneration, and head injuries: mitigation and prevention strategies, supplements, and more | Tommy Wood, M.D., Ph.D.
“If you’re trying to maintain a basic set of cognitive functions, [it is important] to actively work on ways to increase headroom, increase absolute capacity throughout the lifespan. Because at some point capacity will decrease, but you want to push that out as far as you can.” —Tommy Wood
“The cholesterol paradox”: a catchy phrase for an idea with no substance
A recent study reported that hypercholesterolemia is associated with reduced mortality, but it falls short of upsetting conventional wisdom
#255 ‒ Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease and CVD, familial hypercholesterolemia, and more | John Kastelein, M.D., Ph.D.
“One of the things that is so dangerous about this disorder is that the plaque that you get in FH is a soft plaque.” —John Kastelein
#252 ‒ Latest insights on Alzheimer’s disease, cancer, exercise, nutrition, and fasting | Rhonda Patrick, Ph.D.
“My perspective has shifted as any scientist that’s following data should… When new data comes out, you have to reassess things.” —Rhonda Patrick
A new analysis of REDUCE-IT: benefits of omega-3s vs. harm from placebos
A secondary analysis of biomarker data from REDUCE-IT raises questions about the apparent benefits of EPA-derivative icosapent ethyl
#247 ‒ Preventing cardiovascular disease: the latest in diagnostic imaging, blood pressure, metabolic health, and more | Ethan Weiss, M.D.
“If everybody got truly optimal medical therapy, if we didn’t have barriers to using all these tools in everybody, I think this disease would largely be controlled.” —Ethan Weiss
A recent metformin study casts doubts on longevity indications
A new retrospective study contradicts previous evidence of metformin’s potential effects on lifespan extension in a general population, but for real answers, randomized trials are needed.
More hype than substance: erythritol and cardiovascular risk
A newly-published study caught public attention by reporting an association between the common sweetener erythritol and increased risk of heart attack and stroke, but there’s more to the story.